Long COVID-19 fatigue is a difficult problem to treat. In a new study in eClinical Medicine, a relatively small group of people (41) who received the medicine reported positive results over those receiving a placebo. The drug (not available yet) AXA1125 was tied to significant reductions of fatigue, and they could walk farther. Interestingly, it was developed to support multiple metabolic and inflammatory pathways in Non-Alcoholic Fatty Liver Disease.
I am hopeful that we are able to find a treatment for long COVID-19 and other similar post-viral fatigue syndromes. Sufferers often fly under the radar screen or be discounted when they ask for help.
Comments